[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-progressive-aphasiappa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-progressive-aphasiappa":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,58,89,130,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100612951","remotely-supervised-neuromodulation-in-ppa-100612951",false,"NCT07260253","Remotely-supervised Neuromodulation in PPA","Investigating the Benefits of Remotely-Supervised Neuromodulation In Primary Progressive Aphasia","Inclusion Criteria:\n\n* Meets diagnostic criteria for primary progressive aphasia (PPA)\n* Meets diagnostic criteria for logopenic variant PPA\n* Attains score of 15 or higher on the Mini-Mental State Examination\n* Has adequate hearing and vision (with hearing or vision aids, if needed)\n* Is able to travel to research site and undergo MRI brain scan\n* Has access to high speed internet and basic experience using a computer and the internet\n* Is a fluent speaker of English\n* Has a study partner who can co-enroll in the study, attend pre-treatment training at the research site, and be present for teleconference meetings, as needed\n\nExclusion Criteria:\n\n* Speech and language deficits better accounted for by another neurological disorder\n* Does not meet diagnostic criteria for logopenic variant PPA\n* Scores less than 15 on the Mini-Mental State Examination\n* Does not have a study partner who can co-enroll in the study\n* Has contraindications for tDCS or MRI scan (History of seizures, head injury, craniotomy, skull surgery or fracture; History of severe or frequent migraines; Metallic implant in head or any metal in head; Pacemaker or cardioverter-defibrillator or any other stimulator; Chronic skin problems; Pregnancy)\n* Has a history of stroke, epilepsy, or significant brain injury","ALL","40 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn whether home-based brain stimulation combined with virtual speech-language therapy can improve communication abilities in adults with logopenic variant primary progressive aphasia (lvPPA), a language disorder most often caused by Alzheimer's disease.\n\nThe main questions the study aims to answer are:\n\n* Is combining remotely supervised transcranial direct current stimulation (tDCS) with virtual speech-language therapy feasible and acceptable for people with lvPPA?\n* Does this combined treatment lead to improvements in communication compared to speech-language therapy with sham (placebo) stimulation?\n* Do individual brain characteristics help predict who benefits most from this treatment?\n\nResearchers will compare participants who receive active tDCS plus virtual speech-language therapy to participants who receive sham (placebo) tDCS plus virtual speech-language therapy to see if active brain stimulation enhances communication outcomes.\n\nParticipants will:\n\n* Complete speech-language therapy sessions delivered by video visit.\n* Receive either active or sham tDCS that is remotely supervised and completed at home.\n* Complete language and cognitive testing before and after treatment.\n* Undergo brain imaging and other assessments to help understand treatment response.",[26,27,28,29,30,31],"Primary Progressive Aphasia(PPA)","Progressive Aphasia","Progressive Aphasia in Alzheimer's Disease","Logopenic Progressive Aphasia (LPA)","Logopenic Variant Primary Progressive Aphasia","Logopenic Variant of Primary Progressive Aphasia (LPA)",[33,34,35,36,37,38,39,40,41,42,43,44],"lvPPA","PPA","logopenic variant PPA","transcranial direct-current stimulation","tDCS","neuromodulation","speech therapy","speech-language pathology","logopenic","teletherapy","remote","virtual","RECRUITING","2026-06-24",{"date":48,"type":49},"2026-06-29","ACTUAL",{"date":51,"type":49},"2026-04-15",{"date":53,"type":20},"2029-08",{"name":55,"class":56},"Maya Henry","OTHER",2,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100605107","long-term-effect-of-brain-stimulation-in-ppa-100605107","NCT07158216","Long Term Effect of Brain Stimulation in PPA","Long-term Effect of Transcranial Magnetic Stimulation and Transcranial Electrical Stimulation in Primary Progressive Aphasia: Randomized, Double-blind Clinical Trial (RECONNECT-PLUS)","RECONNECT-PLUS","Inclusion Criteria:\n\n* Diagnosis of PPA according to the current consensus criteria proposed by Gorno-Tempini et al., 2011), based on the presence of progressive language impairment as the most prominent and primary cause of functional decline and the exclusion of other medical, psychiatric, or non-neurodegenerative causes,a s well as early prominent memory, visuoperceptual or behavioral disturbances;\n* Diagnosis of one of the three variants of PPA (non-fluent, semantic, or logopenic) according to the consensus criteria (Gorno-Tempini et al., 2011), based on the language profile and supported by neuroimaging (FDG-PET or MRI).\n* Clinical Dementia Rating scale equal or less than 1;\n* The language impairment is the main neurological deficit for the patient.\n\nExclusion Criteria:\n\n* Patient diagnosed with a condition other than PPA that could cause language impairment;\n* History of epilepsy or presence of focal epileptiform pathology on EEG recording; ·Contraindications related to the treatments or procedures to be used (TMS and tDCS), such as ferromagnetic material, pregnancy, or breastfeeding;\n* Terminal illness or active malignancy;\n* Alcohol or substance abuse within the past year;\n* Major psychiatric disorders (schizophrenia, schizoaffective disorders, bipolar disorder, obsessive-compulsive disorder, or personality disorders);\n* Absolute inability to communicate (mutism), or poor command of the language that, in the investigator's judgment, would prevent participation in the study;\n* Severity of PPA that prevents participation in interventions or assessments at the time of inclusion;\n* Participation in another clinical trial within the previous 4 months;\n* Chronic use of medications that could affect study outcomes;\n* Antiepileptic drugs: allowed if on stable doses for at least 3 months before inclusion. If needed during the study due to seizure occurrence, they may be added;\n* Diazepam and derivatives: permitted only if on stable doses for at least 3 months before inclusion. Dose adjustments during the study are allowed;\n* Donepezil, Galantamine, Rivastigmine, and Memantine: allowed if on stable doses for at least 3 months before inclusion;\n* SSRIs (Selective Serotonin Reuptake Inhibitors): permitted only if on stable doses for at least 3 months prior to inclusion. If necessary during the study, they may be added;\n* Medications that may lower the seizure threshold (e.g., tricyclic antidepressants, antipsychotics): allowed if on stable doses for at least 3 months before inclusion.","18 Years",{"count":19,"type":20},[23],"The goal of this clinical trial is to investigate the effect of non-invasive brain stimulation techniques in the progression of primary progressive aphasia for 6 months. We will compare three modalities of brain stimulation (TMS, tDCS, TMS+tDCS) against sham stimulation. All patients will receive also language therapy.",[26],[72,73,74,75,76,77,78],"Primary progressive aphasia","Frontotemporal dementia","Alzheimer's disease","Brain stimulation","Transcranial Magnetic Stimulation","Transcranial direct current stimulation","Transcranial electrical stimulation","2026-04-19",{"date":81,"type":49},"2026-04-23",{"date":83,"type":49},"2025-09-15",{"date":85,"type":20},"2028-12",{"name":87,"class":56},"Hospital San Carlos, Madrid",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":109,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":88},"100609830","intervention-for-communication-quality-of-life-in-primary-progressive-aphasia-100609830","NCT07219680","Intervention for Communication Quality of Life in Primary Progressive Aphasia","Intervention to Promote Communication Quality of Life for Persons With Language-Led Dementia and Their Partners: A Randomized Pilot Trial","Multi-PA","Inclusion Criteria for Persons with PPA:\n\n* A PPA (Gorno-Tempini et al., 2011) or \"PPA-plus\" (Mesulam et al., 2001) diagnosis\n* MMSE score of 15 or higher and must be able to produce single monosyllabic words intelligibly\n* Must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Hearing and vision adequate for participation in teleconference meetings\n* Must have a study partner available (someone who will commit to attending teleconference sessions, as needed, during assessment and treatment phases)\n\nInclusion criteria for Care Partners:\n\n* Partners must express willingness to attend and participate in assessment and treatment sessions, including those targeting dyadic communication goals\n* Partners must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Partner's hearing and vision should be adequate for participation in teleconference meetings\n\nThe participant and\u002For study partner must have basic experience using a computer.\n\nExclusion criteria for persons with PPA:\n\n* Other central nervous system or medical diagnosis that can account for symptoms\n* Psychiatric diagnosis that can account for symptoms",{"count":98,"type":20},30,[23],"The goal of this clinical trial is to learn whether a personalized, multi-component, virtual speech language treatment program can improve communication and quality of life for adults with primary progressive aphasia (PPA) and their primary communication partners. The study will enroll participants who speak English and\u002For Spanish.\n\nThe main questions the study aims to answer are:\n\n* Is the telerehabilitation program feasible and acceptable for people with PPA and their study partners?\n* Do participants with PPA and study partners find treatment beneficial?\n* What patterns of treatment response are seen in participants?\n* Which outcome measures are most useful for evaluating changes in communication and quality of life?\n\nResearchers will compare participants who receive intervention immediately to participants assigned to a waitlist control group (who will receive treatment after a delay) to see whether participation in the treatment program is associated with improvements in communication and quality of life.\n\nParticipants will:\n\n* Take part in speech language therapy sessions delivered by video visit that combine restorative, compensatory, and partner-focused communication strategies. Treatment may take place after a waiting period.\n* Receive education and communication training together with their partner.\n* Complete speech, language, and cognitive assessments.\n* Complete questionnaires about communication abilities, daily functioning, and quality of life.",[26,102,29,103,27,104,105,30,31,106,107,108],"Semantic Dementia","Nonfluent Aphasia, Progressive","Semantic Variant Primary Progressive Aphasia (svPPA)","Semantic Aphasia","Logopenic Progressive Aphasia","Nonfluent Variant Primary Progressive Aphasia (nfvPPA)","Nonfluent Progressive Aphasia",[40,110,41,111,112,113,42,43,114,115,116,117,118,119,120,121,122],"neurodegenerative disease","nonfluent","semantic","script training","multimodal communication training","partner training","augmentative and alternative communication","AAC","Communication Book","bilingual","Spanish","Hispanic","Latino",{"date":124,"type":49},"2026-04-21",{"date":126,"type":49},"2026-04-01",{"date":128,"type":20},"2027-08",{"name":55,"class":56},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":57},"100572953","speech-and-language-interventions-for-italian-people-with-ppa-100572953","NCT06739967","Speech and Language Interventions for Italian People With PPA","Speech and Language-Tailored Interventions for People With Primary Progressive Aphasia","PPA-rehab","Inclusion Criteria:\n\n* Diagnosis of PPA according to the current clinical criteria (Gorno-Tempini et al., 2011)\n* Mild PPA defined using the Progressive Aphasia Severity Scale (PASS)\n* Age between 40 and 85 years\n* Patients with Italian mother tongue\n* Patients with the ability to sign the informed consent\n* Patients with the ability to comply with the study procedures\n* Patients with stable pharmacological treatment for at least 4 weeks.\n\nExclusion Criteria:\n\n* Mini-Mental State Exam (MMSE) Score \\\u003C15\n* Presence of other neurological or psychiatric diseases, including cerebrovascular disease\n* Severe and uncorrected hearing loss or visual disturbances\n* Inability to repeat multi-syllable words (4 syllables)\n* Concurrent participation in other pharmacological and non-pharmacological experimental studies",true,"85 Years",{"count":98,"type":20},"OBSERVATIONAL","Primary progressive aphasia (PPA) is an umbrella term used to refer to several clinical variants that manifest as an insidious deterioration of speech\u002Flanguage skills, usually due to frontotemporal lobar degeneration and\u002For Alzheimer's disease. Consensus criteria have been proposed by an international community regarding the sub-classification of PPA into three variants: (1) semantic variant PPA, characterized by impaired confrontation naming and single-word comprehension; (2) logopenic variant PPA), characterised by word-finding difficulties and sentence repetition deficits; and (3) non-fluent variant, characterised by agrammatism with or without apraxia of speech.\n\nSpeech and language therapists (SLTs) play a crucial role in the diagnostic process and in setting a therapeutic path along with monitoring the evolution of the clinical picture. Despite growing evidence supporting the benefits of speech-language intervention, the frequency with which individuals with PPA are referred for speech and language services, is suboptimal likely due to skepticism regarding the value of speech and language therapy in the context of neurodegeneration, the scarcity of SLTs with expertise in the treatment of PPA, the lack of awareness regarding the role of the SLT amongst referrers, and the geographical barriers that impede access to in-person speech and language services. In Italy, patients with PPA are rarely offered treatment options due to a lack of understanding of the disorder on the part of health professionals and erroneous assumptions regarding the utility of treatment in patients facing a worsening prognosis.\n\nThe primary aim of this pilot study is to develop tailored speech and language interventions for patients with different variants of PPA by addressing their linguistic and cognitive difficulties. Secondly, to explore the intervention's effect also on untreated tasks and assess the long-term maintenance of the proposed interventions by monitoring patients for up to six months. Finally, in each PPA variant, the investigators aim to investigate which variables among the sociodemographic, clinical, linguistic\u002Fcognitive, and brain MRI features at baseline predict successful clinical results, as well as which structural and functional brain changes are associated with speech and language improvements.",[26],[145,146,73,147,34,148,149,150],"Speech and language therapy","online intervention","Alzheimer's disease","Communication Disorders","Neurodegenerative Diseases","Dementia","2026-02-19",{"date":153,"type":49},"2026-02-20",{"date":155,"type":49},"2024-09-01",{"date":157,"type":20},"2026-08-31",{"name":159,"class":56},"Istituti Clinici Scientifici Maugeri SpA",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":138,"sex":16,"minAge":66,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":88},"100417416","upenn-observational-research-repository-on-neurodegenerative-disease-100417416","NCT04715399","UPenn Observational Research Repository on Neurodegenerative Disease","University of Pennsylvania Centralized Observational Research Repository on Neurodegenerative Disease (UNICORN)","UNICORN","Inclusion Criteria:\n\nThis protocol will include 3 groups of people:\n\n1. People with a clinical diagnosis of a neurodegenerative disease. such as frontotemporal degeneration(FTD), primary progressive aphasia(PPA), Lewy body disease(LBD), amyotrophic lateral sclerosis(ALS), progressive supranuclear palsy(PSP), corticobasal syndrome(CBS), posterior cortical atrophy(PCA), Alzheimer's disease(AD), Parkinson's disease(PD)\n2. People with a family history of neurodegenerative disease who may or may not be symptomatic, and may or may not be mutation carriers such as familial frontotemporal lobar degeneration (fFTLD) or familial ALS,\n3. People with no known neurological disease who will provide control data.\n\nExclusion Criteria:\n\n* Anyone who is under the age of 18.\n* Anyone with a condition or in a situation which, in the Investigator's opinion, could confound the study findings or may interfere significantly with a person's participation, including but not limited to neurological, psychological and other medical conditions (such as cardiac, neurosurgical, infectious conditions).\n* Individual participants may be excluded from some, but not all, study procedures for safety reasons when they have a contraindication or at the discretion of the Investigator. For example, persons with metal implants which are not MRI-safe will not be able to take part in imaging, and those on blood thinning medications may not be able to take part in lumbar puncture.\n* Pregnant women; if a woman becomes pregnant during the study, research activities that may increase risk to the patient and the unborn fetus will be stopped until the end of pregnancy, at which point participation can be resumed.",{"count":169,"type":20},1000,"The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.",[172,26,173,174,175,176,177,178,179],"Frontotemporal Degeneration(FTD)","Familial Frontotemporal Lobar Degeneration (fFTLD)","Amyotrophic Lateral Sclerosis(ALS)","Lewy Body Disease(LBD)","Progressive Supranuclear Palsy(PSP)","Corticobasal Syndrome(CBS)","Posterior Cortical Atrophy(PCA)","Alzheimer's Disease(AD)","2026-01-21",{"date":182,"type":49},"2026-01-22",{"date":184,"type":49},"2020-05-29",{"date":186,"type":20},"2070-05-30",{"name":188,"class":56},"University of Pennsylvania"]